インフルエンザワクチンのアメリカ市場 2025年

◆英語タイトル:United States Influenza Vaccines Market Report, Analysis and Forecast to 2025
◆商品コード:DATA8102107
◆発行会社(リサーチ会社):DPI Research
◆発行日:2018年10月
◆ページ数:130
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:米国
◆販売価格オプション(消費税別)
Single UserUSD1,390 ⇒換算¥152,900見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,090 ⇒換算¥229,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDPI Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DPI Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

United States Influenza Vaccines market is set to touch US$ 3.5 Billion threshold by 2025.
“United States Influenza Vaccines Market Report, Analysis and Forecast to 2025” presents an in-depth assessment of the United States influenza vaccines market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for United States influenza vaccines market. The report includes historic data from 2013 to 2017 and forecasts until 2025.

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2025.The report provides clear insight into current and future developments of the united states influenza vaccines market. The report also explores detailed analysis of number of children and adults vaccinated with influenza vaccines in United States from 2013 to 2017 and forecasts to 2025. The report also details the latest information about the influenza vaccines production, supply, and allocation by major companies in United States.

A comprehensive analysis has been done on pricing, distribution & demand and effectiveness of influenza vaccines in United States. It also provides a deep and thorough evaluation of distribution channel & technique of influenza vaccination. It covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, promising influenza vaccines in the clinical development and rapid diagnostic testing for the management of influenza. Key trends in terms of collaboration, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the United States influenza vaccines market.

The report concludes with the profiles of major players in the United States influenza vaccines market. The key market players are evaluated on various parameters such as company overview, influenza vaccines portfolios, sales value analysis and recent development of influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, are making novel technology-based influenza vaccines which is likely to affect the market share during the forecast period.

The major companies dominating this market for its products, services and continuous product developments are:

Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca

The Latest Industry Data Included in this Report:

• United States Influenza Vaccines Market Size & Analysis (2013 – 2025)
• United States Number of Persons Vaccinated with Influenza Vaccines (2013 – 2025)
• United States Number of Children Vaccinated with Influenza Vaccines (2013 – 2025)
• United States Number of Adults Vaccinated with Influenza Vaccines (2013 – 2025)
• United States Influenza Vaccines Pricing Trends & Analysis
• United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
• United States Influenza Vaccines Distribution & Demand (2010 – 2018)
• Effectiveness of Influenza Vaccines in United States (2004 – 2018)
• Rapid Diagnostic Testing for the Management of Influenza
• Distribution Channel & Technique of Influenza Vaccination in United States
• United States Influenza Vaccines Reimbursement Policies & Regulatory System
• Major Deals in United States Influenza Vaccines Market
• Promising Influenza Vaccines in Clinical Development
• Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
• Market Definition for the Specified Topic Along with Identification of Key Driver and Inhibitors for the Market
• A Comprehensive List of Key Market Players Along with the Analysis of their Current
Vaccines Portfolios, Sales Value Analysis and Recent Development

Key questions answered in this research report:

• At what pace is the influenza vaccines market growing in United States? What will be growth trend in future?
• How much number of persons being vaccinated with influenza vaccines during 2013 – 2025?
• What are the key drivers and inhibitors in the current market? What will be the impact of drivers and inhibitors in the future?
• What are the various influenza vaccines available in the United States?
• How is the market predicted to develop in the future?
• Who are the key players in this market space?

【レポートの目次】

1. Executive Summary

2. United States Influenza Vaccines Market Size & Analysis (2013 – 2025)

3. United States Number of Persons Vaccinated with Influenza Vaccines (2013 – 2025)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines

4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Inhibitors

5. United States Influenza Vaccines Pricing Trends & Analysis

6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)

7. United States Influenza Vaccines Distribution & Demand (2010 – 2018)

8. Effectiveness of Influenza Vaccines in United States (2004 – 2018)

9. Rapid Diagnostic Testing for the Management of Influenza

10. Distribution Channel & Technique of Influenza Vaccination in United States

11. United States Influenza Vaccines Reimbursement Policies & Regulatory System
11.1 Reimbursement Policies
11.2 Regulation System

12. Major Deals in United States Influenza Vaccines Market
12.1 Merger & Acquisitions
12.2 Collaboration Deal
12.3 Licensing Agreement
12.4 Exclusive Agreement
12.5 Distribution Agreement

13. Promising Influenza Vaccines in Clinical Development

14. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
14.1 Year 2018
14.2 Year 2017

15. Key Companies Analysis
15.1 Sanofi Pasteur
15.1.1 Business Overview
15.1.2 Influenza Vaccines Portfolio
15.1.3 Influenza Vaccine Value Sales Analysis
15.1.4 Recent Development
15.2 GlaxoSmithKline (GSK)
15.2.1 Business Overview
15.2.2 Influenza Vaccines Portfolio
15.2.3 Influenza Vaccine Sales Value Analysis
15.2.4 Recent Development
15.3 Seqirus
15.3.1 Business Overview
15.3.2 Influenza Vaccines Portfolios
15.3.3 Recent Development
15.4 AstraZeneca
15.4.1 Business Overview
15.4.2 Influenza Vaccines Portfolio
15.4.3 Influenza Vaccine Sales Value Analysis
15.4.4 Recent Development

Table 4–1: BiondVax Pharmaceuticals Ltd. Clinical Trials
Table 5–1: United States Pediatric Influenza Vaccines Price, 2018 – 2019
Table 5–2: United States Adult Influenza Vaccine Price, 2018 – 2019
Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation
Table 7–1: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 7–2: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 7–3: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 7–4: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2018
Table 9–1: Influenza Virus Testing Methods
Table 10–1: Distribution of Influenza Vaccination
Table 11–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 12–1: Merger & Acquisitions in Influenza Vaccines Market (Million US$),2003 – 2017
Table 12–2: Collaboration Deal in Influenza Vaccines Market,2007 – 2018
Table 12–3: Licensing Agreement in Influenza Vaccines Market,2007 – 2018
Table 12–4: Exclusive Agreement in Influenza Vaccines Market,2009 – 2016
Table 12–5: Distribution Agreement in Influenza Vaccines Market,2005 – 2016


Figure 2–1: United States Influenza Vaccines Market (Million US$),2013 – 2017
Figure 2–2: United States Influenza Vaccines Market Forecast (Million US$),2018 – 2025
Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2017
Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2018 – 2025
Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2017
Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2018 – 2025
Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2017
Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2018 – 2025
Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2018
Figure 10–1: United States Place of Influenza Vaccination for Children and Adults,2017 - 2018
Figure 15–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2017
Figure 15–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2018 – 2025
Figure 15–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2017
Figure 15–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2018 – 2025
Figure 10–5: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2011 – 2015



【掲載企業】

Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インフルエンザワクチンのアメリカ市場 2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆